Company Interview / Artrya's hearty new tie-up with Sonic

Key points:

Artrya (ASX:AYA) partners with Sonic Healthcare (ASX:SHL) to deploy AI in Australian radiology centresAI advances heart disease diagnostics, enhancing clinician capabilitiesArtrya anticipates FDA approvals, providing confidence against broker sell ratings

Matt Regan from Artrya states their AI company secures a multi-year contract with Sonic Healthcare Australia. This partnership aims to introduce AI technology in 27 radiology centres, enhancing heart disease diagnosis. The deal, while not hugely revenue-driving, validates Artrya's tech.

Matt highlights Artrya’s AI-driven diagnostic tools for heart disease, a leading global killer. The AI rapidly identifies coronary artery issues, supporting clinicians worldwide. Competition in AI is rising, but Matt values its role in boosting productivity without replacing jobs.

Matt shares expectations of gaining FDA clearance by March, with confidence bolstered by FDA responses. He addresses broker sell ratings by focusing on Artrya's optimism for multiple FDA clearances this year, aiming for significant US market revenue.